Skip to main content
. 2013 Jul 17;36(Suppl 2):S245–S252. doi: 10.2337/dcS13-2004

Figure 1.

Figure 1

Odds ratio and 95% CIs for chronic pancreatitis in studies examining the risk of pancreatitis in patients with type 2 diabetes receiving treatment with the GLP-1 receptor agonist exenatide (A) or the DPP-4 inhibitor sitagliptin (B) relative to other glucose-lowering medications. Analysis of claims databases capturing both prescriptions of specific medications and (hospitalization due to) acute pancreatitis. Data depicted in this figure have been taken from refs. 2126.